Use of cellular biotechnologies in treatment metastatic pericarditis at patients with tumors of female reproductive system
https://doi.org/10.17650/1994-4098-2013-0-3-4-101-104
Abstract
Malignant pericardial effusions often arise in patients with breаst cancer and ovarian cancer. Sistem antitumor therapy is uneffective in gen- erally and causes side effects. Here we show that intrapericardial interleukin-2 with allogenеc lymphokine-activated killers and interleukin-2 immunotherapy demonstrated the high efficacy in threatment of breаst and ovarian cancer patients with malignant pericardial effusions. The objective effect was 92.3 % аnd 90.0 % accordingly. These results indicates that intrapericardial immunotherapy might be one of the stages of combined treatment of such group of patients. The suggested type of biotherapy increases the survival and life quality of patients.
About the Authors
K. S. Titov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
S. M. Volkov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. V. Demidov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. N. Gritsay
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
N. I. Lazareva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. V. Kiselevskiy
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. P. Nikolayev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Buzaid A.C., Garewal H.S., Greenberg B.R. Managing malignant pericardial effusion. West J Med 1989;150(2):174–9.
2. Kainuma S., Masai T., Yamauchi T. et al. Primary malignant pericardial mesothelioma presenting as pericardial constriction. Ann Thorac Cardiovasc Surg 2008;14(6):396–8.
3. Verleye L., Thomakos N., Edmondson R.J. Recurrent cervical cancer presenting as malignant pericarditis: case report and review of the literature. Еur J Gynaecol Oncol 2009;30(2):193–5.
4. Maisch B., Karatolios K. New possibilities of diagnostics and therapy of pericarditis. Internist (Berl) 2008;49(1):17–26.
5. Keane D., Jackson G. Managing recurrent malignant pericardial effusions. BMJ 1992;305(6856):729–30.
6. Vaitkus P.T., Herrmann H.C., LeWinter M.M. Treatment of malignant pericardial effusion. JAMA 1994;272(1):59–64.
7. Cornily J.C., Pennec P.Y., Castellant P. et al. Cardiac tamponade in medical patients: a 10- year follow-up survey. Cardiology 2008;111(3):197–201.
8. Lestuzzi C., Lafaras C., Bearz A. et al. Malignant pericardial effusion: sclerotherapy or local chemotherapy? Br J Cancer 2009;101:734–5.
9. Kaira K., Mori M. Intrapericardial instillation of mitomycin C in recurrent cardiac tamponade due to malignant pericardial effusion. Clin Oncol 2006;18(6):506.
10. Toh U., Fujii T., Seki N. et al. Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion. Cancer Immunol Immunother 2006;55(10):1219–27.
11. Ueno Y., Kohgo Y., Sasagawa Y. et al. A case of pericarditis carcinomatosa showing good response following local transfer of lymphokine-activated killer (LAK) cells. Gan To Kagaku Ryoho 1987;14(8):2579–82.
Review
For citations:
Titov K.S., Volkov S.M., Demidov L.V., Gritsay A.N., Lazareva N.I., Kiselevskiy M.V., Nikolayev A.P. Use of cellular biotechnologies in treatment metastatic pericarditis at patients with tumors of female reproductive system. Tumors of female reproductive system. 2013;(3-4):101-104. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-3-4-101-104
Views:
425
Email this article 